ArticleBreast cancer (Tokyo, Japan)2025
Clinicopathological significance of androgen receptor expression and tumor infiltrating lymphocytes in triple-negative breast cancer: a retrospective cohort study.
Article in Breast cancer (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Androgen Receptor Expression and T-Lymphocyte Infiltration as Prognostic Indicators in Triple-Negative Breast Cancer: A Retrospective Study.Biomedicines · 2026Article
- Efficacy of perioperative pembrolizumab for triple-negative breast cancer with apocrine feature or metaplastic carcinoma.The oncologist · 2026Article
- Reply to the letter to the editor "Pembrolizumab added to neoadjuvant chemotherapy may improve pathological complete response in androgen-receptor positive and low tumor-infiltrating lymphocytes triple-negative breast cancer patients".Breast cancer (Tokyo, Japan) · 2025Article
- Pembrolizumab added to neoadjuvant chemotherapy may improve pathological complete response in androgen-receptor positive and low tumor-infiltrating lymphocytes triple-negative breast cancer patients.Breast cancer (Tokyo, Japan) · 2025Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
backgroundTriple-negative breast cancer (TNBC) is a serious disease with limited treatment options. We explored the significance of androgen receptor (AR) expression and tumor-infiltrating lymphocytes (TILs) in predicting neoadjuvant chemotherapy (NAC) resistance in TNBC, hypothesizing that AR/TIL classification using pretreatment biopsies can identify NAC-resistant subgroups and improve the understanding of apocrine differentiation.
methodsThis retrospective study included 156 consecutive patients with TNBC treated with NAC. AR immunostaining was defined positive if ≥ 1% of the tumor cell nuclei were stained. Stromal TIL levels were assessed, with high levels defined as ≥ 50%. Apocrine differentiation was detected using an anti-15-PGDH antibody. The pathological response to NAC was evaluated.
resultsOverall, 36% (n = 56) of the patients achieved a pathological complete response (pCR). AR
conclusionsAR/TIL classification using pretreatment biopsies identified TNBC subgroups with distinct NAC responses and prognoses. AR
Indexed as
Identifiers
39729292What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.